XORTX Therapeutics Inc (XRTX): Debt to Book Capitalization Ratio
The historical debt-to-book capitalization ratio for XORTX Therapeutics Inc. (XRTX) demonstrates volatility, as patent battles with industry behemoths create risks. This trend reflects the prolonged formation of distribution chains within the renal therapy sector. The value is currently held at 0.00, while the high pricing power of XORTX Therapeutics Inc. (XRTX) is based on unique proprietary forms of oxypurinol for the treatment of polycystic kidney disease.
&width=1200&height=400&colorIndex=0&v=mvt4kixj.9g-7avve2o&start=20220704&end=20261029&filename=GURU_Markets_-_XRTX_-_XORTX-Therapeutics-Inc._-_Debt-to-Net-Assets-Ratio "XRTX: XORTX Therapeutics Inc. Debt to Book Capitalization Ratio 07/04/2022 - 10/29/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for XORTX Therapeutics Inc (XRTX)
- current price and projected stock value:
- stock exchange capitalization data:
- book value of equity indicators:
- debt and solvency information:
Total Debt to Equity Ratio XORTX Therapeutics Inc.|XRTX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital XORTX|XRTX - Company Total Debt Obligations|Debt to Book Capitalization Ratio XORTX Corp|XRTX - Company Long-Term Liabilities|Company Short-Term Debt XORTX Therapeutics|Quick Liquidity Indicator xortx.com
- business earnings and investment ratios data:
Comprehensive company analysis:XRTX (XORTX Therapeutics Inc.)
XORTX Therapeutics Inc. (XRTX) is developing complex drugs for the treatment of rare kidney diseases within a strictly regulated environment. This ratio compares the volume of borrowed funds to equity, measuring the business's level of financial autonomy. Investors use this balance to assess the company's resilience to potential share dilution. Sharp spikes in the total debt-to-equity ratio signal a critical overheating of the debt load. Monitoring this metric allows for the timely identification of solvency risks.
Competitors of XORTX Therapeutics Inc. (XRTX)
Debts to Book Capitalization ARGX (argenx SE)|Debts to Book Capitalization biontech.de BNTX|ABVX - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio ADMA (ADMA Biologics Inc)|Protagonist Therapeutics Inc (PTGX) - Debt to Book Capitalization Ratio|Debt to Book Value Immunovant Therapeutics|KNSA (Kiniksa Pharmaceuticals) - Debts to Book Capitalization|Debts to Book Capitalization grifols.com|Debt to Book Value ADPT (Adaptive Biotechnologies Corporation)|CLDX (Celldex Therapeutics Inc) - Debt to Net Assets Ratio|Debts to Book Capitalization AUPH (Aurinia Pharma)|Debts to Net Assets BioCryst Corp (BCRX)|VERA - Debt to Book Capitalization Ratio|dianthustx.com (DNTH) - Debt to Book Value|Pharvaris (PHVS) - Debt to Book Capitalization Ratio|Debt to Book Value AbCellera Bio|Debt to Book Value TRML|Debts to Book Capitalization Precigen Corp|Debt to Book Capitalization Ratio Pharming Group N.V. (PHAR)|nektar.com - Debt to Book Value Ratio|Debts to Book Capitalization UPB (Upstream Bio)|Zenas Bio (ZBIO) - Debts to Book Value|IMNM: Debt to Book Value|GOSS (Gossamer Bio Corp.) - Debt to Book Value Ratio|KalVista Pharmaceuticals (KALV) - Debt to Book Capitalization Ratio|Debts to Book Value septerna.com (SEPN)|Debt to Book Capitalization Ratio Pieris Pharmaceuticals, Inc.|SVRA: Debt to Net Assets Ratio|Debt to Book Value RIGL (Rigel Pharmaceuticals Inc)|Debt to Book Capital ANAB|Astria Therapeutics - Debt to Book Value|ENGN: Debt to Book Value Ratio|RAPT: Debt to Book Value|Debt to Net Assets Ratio JBIO (Aerovate Therapeutics Inc)|ACRS (Aclaris) - Debt to Book Value|KYTX: Debt to Book Capital|TLSA (Tiziana Life Sciences) - Debts to Book Capitalization|CABA: Debt to Net Assets Ratio|Debts to Book Capitalization VTYX|THTX - Debts to Book Value|Debt to Book Capitalization Ratio Avalo Therapeutics Inc. AVTX|Debt to Net Assets Ratio ELDN|Agenus - Debts to Book Capitalization|CLYM - Debts to Book Capitalization|Zura Bio Limited (ZURA) - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio ATYR (aTyr Pharma Inc)|ADAG (Adagene Inc) - Debts to Book Capitalization|Debts to Book Value Ikena Oncology, Inc. IMA|Debt to Book Value STTK (Shattuck Labs, Inc.)|Debts to Book Capitalization equilliumbio.com (EQ)|Connect Biopharma Holdings Limited - Debt to Book Value|Debt to Book Capital IMUX (Immunic Therapeutics)|Atara Biotherapeutics Inc - Debts to Book Capitalization|Debts to Net Assets InflaRx N.V. IFRX|XFOR: Debts to Book Capitalization|Debt to Book Value Adicet Bio, Inc.|Debt to Book Capitalization Ratio Celularity Inc|INmune Bio Inc (INMB) - Debts to Net Assets|Debt to Book Value BRNS (Barinthus Bio)|KZR (Kezar Life Sciences Inc) - Debt to Net Assets Ratio|Debts to Book Capitalization SABS (SAB Biotherapeutics)|Debts to Net Assets akaritx.com (AKTX)|ENLV - Debt to Book Capitalization Ratio|QTTB (Q32 Bio Inc.) - Debt to Book Value Ratio|GOVX: Debts to Book Capitalization|Debt to Book Value Edesa Biotech Corp|Debt to Book Value IBIO|Carisma Tx (CARM) - Debts to Net Assets|Debt to Book Value XTLB (XTL Biopharmaceuticals Ltd.)|boltbio.com - Debt to Book Value Ratio|Debt to Book Capitalization Ratio HCW Biologics HCWB|Debt to Net Assets Ratio APVO|AIM: Debt to Book Value|Aditxt - Debt to Book Capital|GRI (GRI Bio) - Debt to Book Value|Debt to Book Value Ratio HIND|Debt to Book Capitalization Ratio Revelation Bio|Indaptus Corp - Debts to Book Capitalization Ratio|Debts to Book Capitalization SCNI|CALI (calcimedica.com) - Debt to Net Assets Ratio|Debts to Book Capitalization AFMD (Affimed N.V.)|Debts to Book Capitalization Allakos Inc ALLK|HOOK - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio IGMS (IGM Biosciences, Inc.)|iTeos Therapeutics (ITOS) - Debt to Book Capitalization Ratio|Debt to Book Value oceanbiomedical.com|TCBP (TC BioPharm) - Debts to Book Capitalization|Debts to Book Capitalization Third Harmonic Bio Inc.